Breast cancer treatment: When less is more

Breast Cancer Treatment: When Less is More – Evidence Dossier Source: PLOS Medicine, October 26, 2026, article by Katarzyna Starowicz on behalf of the PLOS Medicine Staff Editors What is Established Breast cancer mortality has declined annually by approximately 2% to 2.5% over the past decade in many high-income countries, largely due…

Burden of bacterial antimicrobial resistance associated with modifiable human antibiotic consumption: An observational study

Burden of bacterial antimicrobial resistance linked to modifiable antibiotic use: An Evidence Dossier This article summarizes findings from a 2026 observational study published in PLOS Medicine investigating the relationship between human antibiotic consumption and bacterial antimicrobial resistance (AMR) on a global scale. The study analyzes data from over 30 million bacterial isolates…

Outcomes of home-based versus facility-based care for mild diphtheria during a large epidemic in Kano State, Nigeria: A retrospective matched cohort study

Outcomes of Home-Based Versus Facility-Based Care for Mild Diphtheria During a Large Epidemic in Kano State, Nigeria This article summarizes evidence from a retrospective matched cohort study published in PLOS Medicine (October 2026) examining the results of home-based care compared to facility-based care for mild diphtheria cases during a major epidemic in…

Human medicines European public assessment report (EPAR): Vokanamet, canagliflozin,metformin, Date of authorisation: 23/04/2014, Revision: 26, Status: Authorised

What is established Vokanamet is an authorized diabetes medication in the European Union that combines two active substances: canagliflozin and metformin. It is used to manage blood glucose levels in adults with type 2 diabetes when metformin alone or other diabetes treatments do not sufficiently control blood sugar. The drug was authorized…

Parting words from a scholar who stepped up

What is established Tomiko Brown-Nagin, a noted legal scholar and historian, served as dean of the Harvard Radcliffe Institute for eight years before deciding to become the James Quillen Dean of Stanford University’s Graduate School of Education. During her tenure at Harvard, she led significant university-wide initiatives addressing the institution’s historical ties…

Position paper on clinical development of Bundibugyo vaccines

Evidence Dossier: Clinical Development of Bundibugyo Ebola Vaccines What is Established Bundibugyo virus is a species of Ebola virus associated with outbreaks of Ebola virus disease (EVD) in humans. Like other Ebola viruses, it causes severe hemorrhagic fever with high mortality rates. Vaccination efforts for Ebola have primarily targeted the Zaire strain,…

AMA and EMA issue joint guidance on Ebola vaccine development

What is established In October 2026, the European Medicines Agency’s Emergency Task Force (EMA’s ETF) and the African Medicines Agency (AMA) jointly published a position paper providing guidance on the development of vaccines targeting Ebola disease caused by the Bundibugyo virus (BDBV). This action follows a scientific consultation held in August 2026,…

Smugglers Collected Up to $509M on Europe Routes in 2025

Smugglers’ Revenue from Mediterranean and Atlantic Migration Routes to Europe in 2025: Evidence Dossier What is established New research conducted by the United Nations Office on Drugs and Crime (UNODC) estimates that in 2025, criminal smuggling networks collected between $388 million and $509 million by facilitating sea crossings to Europe. The data…

Human medicines European public assessment report (EPAR): Filgrastim Hexal, filgrastim, Date of authorisation: 06/02/2009, Revision: 27, Status: Authorised

What is established Filgrastim Hexal is an authorised biosimilar medicine approved by the European Medicines Agency (EMA). It contains the active substance filgrastim, a recombinant form of human granulocyte colony stimulating factor (G-CSF), which stimulates the production of neutrophils, a type of white blood cell. Filgrastim Hexal is used to reduce neutropenia…